Drug and Gene Delivery Devices Market Size, Share, and Trends 2025 to 2034

Drug and Gene Delivery Devices Market Size and Forecast 2025 to 2034

The global drug and gene delivery devices market size was estimated at USD 726.42 million in 2024 and is anticipated to reach around USD 1,738.73 million by 2034, expanding at a CAGR of 9.12% from 2025 to 2034. The rising incidence of chronic diseases is a key factor driving the growth of the market. Moreover, technological innovations in gene therapy fuels market growth.

Drug and Gene Delivery Devices Market Key Takeaways

• North America dominated the global drug and gene delivery devices market with the largest market share of 40.45% in 2024.
• Asia Pacific is expected to grow at a solid CAGR of 10% during the forecast period.
• By vector, the viral vector segment contributed the highest market share of 91% in 2024.
• By vector, the non-viral vector segment is projected to grow at a healthy CAGR of 12.3% during the forecast period.
• By delivery type, the oral segment has held the maximum market share of 53% in 2024.
• By delivery type, the injectable  segment is expected to expand at a healthy CAGR of 11.2% during the forecast period.

Impact of Artificial Intelligence on the Drug and Gene Delivery Devices Market

AI technology has the ability to transform drug and gene delivery devices, streamlining therapy and reducing side effects. Furthermore, AI algorithms help researchers predict drug release profiles and facilitate dosage regimens to get efficient therapies. AI-enabled devices monitor patient adherence to medication and provide real-time feedback, improving safety, reliability, and efficacy.

U.S. Drug and Gene Delivery Devices Market Size and Growth 2025 to 2034

The U.S. drug and gene delivery devices market size was evaluated at USD 238.01 million in 2024 and is predicted to be worth around USD 573.91 million by 2034, rising at a CAGR of 9.20% from 2025 to 2034.

North America dominated the global drug and gene delivery devices market with the largest market share of 40.45% in 2024, in terms of revenue and is estimated to sustain its dominance during the forecast period. This is attributed to the increased number of people suffering from various chronic diseases. According to a study, around 60% of the US population is suffering from at least one chronic diseases. Moreover, the development of various therapeutics and innovative drugs that can effectively treat chronic diseases and genetic diseases is fueling the demand for the drug and gene delivery devices market. Moreover, the rising popularity of personalized medicines may impact the market positively in the forthcoming years.

Asia Pacific is expected to grow at a solid CAGR of 10% during the forecast period. This is attributed to the rising prevalence of various chronic and infectious diseases, rapidly growing biopharmaceutical industry, presence of huge population, and rising prevalence of diseases caused by pollution owing to the rapid industrialization and urbanization.

Drug and Gene Delivery Devices Market Growth Factors

The rising prevalence of various chronic diseases such as cancer, diabetes, cardiovascular diseases, and other chronic diseases coupled with the technological advancements in the drug delivery has propelled the growth of the global drug and gene delivery devices market. According to the International Agency for Research on Cancer The global cancer cases are estimated to grow by 47% from 2020 to 2040. It is expected that 28.4 million cases will be recorded in 2040, globally. Moreover, the increasing investments in the research and development by the top players in the field of genomics is driving the market growth. The shifting preferences of the patients and the doctors has propelled the demand for the drug and gene delivery devices. The introduction of auto injectors, biopharmaceutical classification systems, implants in customizable shapes and sizes, and smartcards and adaptive aerosol delivery systems have contributed significantly towards the development of the global drug and gene delivery devices market.

The rising adoption of the gene therapeutics and innovative drugs owing to the rising awareness regarding the availability of new drugs that can effectively cure the chronic diseases has fueled the demand for the drug and gene delivery devices. The rising investments in the research and development of the new drugs and therapies for treating the incurable diseases is among the significant drivers of the market. Moreover, the rapid growth of the biopharmaceutical industry across the globe is expected to play a crucial role during the forecast period. The presence of the numerous market players and the various strategies such as new product launches, acquisitions, mergers, and partnerships adopted by them highly influences the market growth. Therefore the rising penetration of the drug and gene delivery devices companies across the globe is boosting the market growth significantly.

Market Scope

Delivery Type Insights

The oral segment has held the maximum market share of 53% in 2024 in terms of revenue and is estimated to sustain its dominance during the forecast period. The oral drug delivery is the most convenient and most popular route of administration all over the globe. It is economical, pain-free, and self-administered type of delivery where no sterile precautions are involved. Moreover, the development of various therapeutics that can identify the affected cell and can treat that cell without harming the normal cells is exponentially boosting the growth of this segment. Therefore, the rapid growth of the biosimilar, targeted therapeutics, and gene therapies had positively impacted the market growth in the past few years.

The injectable  segment is expected to expand at a healthy CAGR of 11.2% during the forecast period. The technological advancements in the injectable devices has propelled the adoption of the self-injectable devices among the patients. The rising number of diabetic population is fostering the growth of this segment as the diabetic patient need to regularly inject insulin. The increasing popularity of the self-injectors, needle-free injectors, pen-injectors, and auto-injectors has allowed the patients to conveniently administer drugs from the convenience of their home, eliminating the medical assistance. All these factors are estimated to have a significant impact on the drug and gene delivery devices market and will foster the demand for the injectable segment in the forthcoming years.

Method Insights

Based on method, the in situ segment accounted largest revenue share in 2024 and is projected to remain its dominance during the forecast period. This can be attributed to the certain advantages associated with the in situ method such as low complication in fabrication and ease of drug administration. Moreover, the majority of the drugs that are currently used follows the in situ method.

Vector Insights

The viral vector segment contributed the highest market share of 91% in 2024. Most of the clinical trials that are based on the gene therapies are dependent on the viral vectors for transfection. The rising prevalence of the genetic diseases is the major factors that boosts the growth of this segment. The extensive usage of viral vectors in the treatment of various chronic diseases has fueled the segment’s growth in the past few years.

The non-viral vector segment is projected to grow at a healthy CAGR of 12.3% during the forecast period. This can be attributed to the increasing number of clinical trials related to cardiovascular diseases that uses non-viral vectors as the gene transfer mode. The rising number of cardiovascular diseases among the global population is expected to foster the growth of this segment.

Key Companies & Market Share Insights

The market is moderately fragmented with the presence of several local companies. These market players are striving to gain higher market share by adopting strategies, such as investments, partnerships, and acquisitions & mergers. Companies are also spending on the development of improved products. Moreover, they are also focusing on maintaining competitive pricing.

The various developmental strategies like acquisitions and mergers fosters market growth and offers lucrative growth opportunities to the market players.

Drug and Gene Delivery Devices Market Companies

• Pfizer, Inc.
• F. Hoffmann-La Roche Ltd.
• Johnson and Johnson Private Ltd.
• Novartis AG
• Bayer AG
• Becton, Dickinson and Company
• Uniqure NV

Latest Announcements by Industry Leaders

• In February 2024, Johnson & Johnson announced Robert Langer, Sc.D., of Massachusetts Institute of Technology (MIT) as the winner of the 2023 Dr. Paul Janssen Award for Biomedical Research. Dr. Langer was honored for his groundbreaking work in designing novel drug delivery systems that can deliver medications continuously, precisely, and at controlled rates over extended periods. 

Recent Developments

• In September 2024, Evonik expanded its EUDRACAP portfolio with a new functional, ready-to-fill capsule that enables the delivery of sensitive active ingredients to the ileo-colonic region. EUDRACAP colon is designed to deliver sensitive active ingredients, such as live biotherapeutic products (LBPs) to treat or prevent a wide range of diseases, to the ileo-colonic region.
• In February 2024, UT Southwestern collaborated with Pfizer to develop enhanced RNA delivery technologies for genetic medicine therapies through the Dallas-based medical center’s Program in Genetic Drug Engineering.

Segments Covered in the Report

By Delivery Type

• Oral
• Ocular
• Inhalation
• Nasal
• Injectable
• Transdermal
• Topical

By Method

• In Situ
• Ex Vivo

By Vector

• Viral Vector
• Non-Viral Vector

By Geography

• North America
• Asia Pacific
• Europe
• Latin America
• Middle East and Africa